Sun Pharma sinks 7% on warning letter but analysts bullish
However, most analysts are still bullish on the stock and are keenly waiting to for more details in the warning letter. Few analysts have lowered target price with a cautious outlook. Phillip Capital remains positive and advises to buy on dips stating that the issue may have more sentimental impact.